Certara, Inc. (NASDAQ:CERT) Director Mason P. Slaine sold 376,149 shares of the stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $29.74, for a total transaction of $11,186,671.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Certara stock opened at $28.50 on Thursday. The stock has a market cap of $4.55 billion and a P/E ratio of -67.86. The company has a debt-to-equity ratio of 0.30, a current ratio of 7.25 and a quick ratio of 7.25. Certara, Inc. has a 1 year low of $23.75 and a 1 year high of $45.48. The firm’s 50 day moving average price is $36.78 and its 200-day moving average price is $31.24.
Certara (NASDAQ:CERT) last released its quarterly earnings data on Monday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $73.94 million for the quarter, compared to analysts’ expectations of $73.90 million. Certara had a negative net margin of 21.07% and a negative return on equity of 2.85%. As a group, equities analysts expect that Certara, Inc. will post 0.1 EPS for the current year.
Several equities analysts have recently weighed in on CERT shares. Zacks Investment Research upgraded shares of Certara from a “sell” rating to a “hold” rating in a research note on Monday, November 15th. Robert W. Baird raised their target price on shares of Certara from $32.00 to $41.00 and gave the stock an “outperform” rating in a research note on Friday, September 17th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $36.33.
Certara Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.